Real-world efficacy of nivolumab plus ipilimumab combination therapy versus nivolumab monotherapy for Stage IV melanoma patients in Asia

被引：1
|
作者：
Maeda, Takuya [1 ]
Hiura, Azusa [1 ]
Uehara, Jiro [1 ]
Toyoshima, Rino [1 ]
Nakagawa, Tomoe [1 ]
Yoshino, Koji [1 ]
机构：
[1] Tokyo Metropolitan Canc & Infect Dis Ctr Komagome, Dept Dermatol Oncol, Tokyo, Japan
来源：
EUROPEAN JOURNAL OF DERMATOLOGY | 2021年 / 31卷 / 05期
关键词：
JAPANESE PATIENTS; SAFETY;
D O I：
10.1684/ejd.2021.4139
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：662 / 664
页数：3
相关论文
共 50 条
  • [1] Real-world efficacy of nivolumab plus ipilimumab combination therapy versus nivolumab monotherapy for Stage IV melanoma patients in Asia
    Takuya Maeda
    Azusa Hiura
    Jiro Uehara
    Rino Toyoshima
    Tomoe Nakagawa
    Koji Yoshino
    European Journal of Dermatology, 2021, 31 : 662 - 664
  • [2] Real-world efficacy and safety data of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanoma
    Takahashi, Akira
    Namikawa, Kenjiro
    Ogata, Dai
    Nakano, Eiji
    Jinnai, Shunichi
    Nakama, Kenta
    Tsutsui, Keita
    Muto, Yusuke
    Mizuta, Haruki
    Yamazaki, Naoya
    JOURNAL OF DERMATOLOGY, 2020, 47 (11): : 1267 - 1275
  • [3] HEALTHCARE COST COMPARISON ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB VERSUS NIVOLUMAB MONOTHERAPY AND IPILIMUMAB MONOTHERAPY IN ADVANCED MELANOMA
    Potluri, R.
    Bhandari, H.
    Ranjan, S.
    Moshyk, A.
    Kotapati, S.
    VALUE IN HEALTH, 2019, 22 : S72 - S73
  • [4] Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
    Ravi Potluri
    Sandip Ranjan
    Hitesh Bhandari
    Helen Johnson
    Andriy Moshyk
    Srividya Kotapati
    Experimental Hematology & Oncology, 8
  • [5] Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
    Potluri, Ravi
    Ranjan, Sandip
    Bhandari, Hitesh
    Johnson, Helen
    Moshyk, Andriy
    Kotapati, Srividya
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2019, 8 (1)
  • [6] Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma
    Parakh, Sagun
    Randhawa, Manreet
    Nguyen, Bella
    Warburton, Lydia
    Hussain, Mohammad Akhtar
    Cebon, Jonathan
    Millward, Michael
    Yip, Desmond
    Ali, Sayed
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 (01) : 26 - 30
  • [7] Real-world outcomes of ipilimumab plus nivolumab for advanced melanoma in the Netherlands
    van Zeijl, M. C. T.
    Wouters, M. W. J. M.
    van den Eertwegh, A. J. M.
    de Wreede, L. C.
    Aarts, M. J. B.
    van Akkooi, A. C. J.
    Van den Berkmortel, F. W. P. J.
    de Groot, J. W.
    Boers-Sonderen, M. J.
    van der Hoeven, J. J. M.
    Hospers, G. A. P.
    Kapiteijn, E.
    Piersma, D.
    van Rijn, R. S.
    Suijkerbuijk, K. P. M.
    Ten Tije, A. J.
    Van der Veldt, A. A. M.
    Vreugdenhil, G.
    Haanen, J. B. A. G.
    ANNALS OF ONCOLOGY, 2019, 30
  • [8] Adverse events of nivolumab plus ipilimumab versus nivolumab plus cabozantinib: a real-world pharmacovigilance study
    Oka, Yurie
    Matsumoto, Jun
    Takeda, Tatsuaki
    Iwata, Naohiro
    Niimura, Takahiro
    Ozaki, Aya Fukuma
    Bekku, Kensuke
    Hamano, Hirofumi
    Araki, Motoo
    Ishizawa, Keisuke
    Zamami, Yoshito
    Ariyoshi, Noritaka
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2024, 46 (03) : 745 - 750
  • [9] COMPARISON OF HEALTHCARE COSTS IN FRANCE OF COMBINATION NIVOLUMAB AND IPILIMUMAB TREATMENT VERSUS NIVOLUMAB MONOTHERAPY AND IPILIMUMAB MONOTHERAPY IN ADVANCED MELANOMA
    Bregman, B.
    Moshyk, A.
    Johnson, H. M.
    Potluri, R.
    Bhandari, H.
    Ranjan, S.
    VALUE IN HEALTH, 2020, 23 : S441 - S441
  • [10] Neoadjuvant nivolumab versus combination ipilimumab and nivolumab followed by adjuvant nivolumab in patients with resectable stage III and oligometastatic stage IV melanoma: preliminary findings
    Reddy, Sangeetha M.
    Amaria, Rodabe N.
    Spencer, Christine N.
    Tetzlaff, Michael
    Reuben, Alexandre
    Andrews, Miles
    Wang, Linghua
    Woodman, Scott
    Zhu, Haifeng
    Blando, Jorge
    Vence, Luis
    Zhang, Shaojun
    Jiang, Hong
    Gopalakrishnan, Vancheswaran
    Hudgens, Courtney
    Wani, Khalida
    Tawbi, Hussein
    Diab, Adi
    Glitza, Isabella
    Patel, Sapna
    Hwu, Wen-Jen
    Wong, Michael
    Hwu, Patrick
    Cormier, Janice
    Lucci, Anthony
    Royal, Richard
    Lee, Jeffrey E.
    Simpson, Lauren
    Burton, Elizabeth M.
    Gershenwald, Jeffrey E.
    Ross, Merrick
    Allison, James
    Sharma, Padmanee
    Davies, Michael
    Wargo, Jennifer
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
12345